` PBYI (Puma Biotechnology Inc) vs S&P 500 Comparison - Alpha Spread

PBYI
vs
S&P 500

Over the past 12 months, PBYI has underperformed S&P 500, delivering a return of 9% compared to the S&P 500's 9% growth.

Stocks Performance
PBYI vs S&P 500

Loading
PBYI
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
PBYI vs S&P 500

Performance Gap Between PBYI and GSPC
HIDDEN
Show

Performance By Year
PBYI vs S&P 500

Loading
PBYI
S&P 500
Add Stock

Competitors Performance
Puma Biotechnology Inc vs Peers

S&P 500
PBYI
ABBV
AMGN
GILD
VRTX
Add Stock

Puma Biotechnology Inc
Glance View

Market Cap
161.7m USD
Industry
Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 196 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

PBYI Intrinsic Value
HIDDEN
Show
Back to Top